According to a new report published by K D Market Insights, titled, “Genitourinary drugs Market Insights, Trends, Opportunity & Forecast, 2023–2032,” the global genitourinary drugs market size is anticipated to witness moderate growth during the forecast period i.e., 2023-2032. The growing incidence of genitourinary issues, inclusive of urinary tract infections, erectile dysfunction, and prostate most cancers, propel the demand for efficient and reliable drugs, the developing geriatric populace gives vast increase capability, the increasing healthcare enterprise, especially in developing areas and the arrival of digital generation integration in healthcare which are the major factors augmenting the growth of the global genitourinary drugs market. The global genitourinary drugs market is anticipated to grow at a moderate CAGR of 3.4% from 2023 to 2032. The market's revenue surged to $33.0 billion in 2022, and it is expected to further accelerate, reaching a notable $46.5 billion by 2032.
growing incidence of genitourinary problems, consisting of urinary tract infections, erectile disorder, and prostate cancer, propel the demand for efficient and dependable drugs. Additionally, technological advancements, are further expected to create ample growth opportunities for the global genitourinary drugs market during the forecast period i.e., 2023-2032. Moreover, the growing awareness around genitourinary health and the need for specialized care, has propelled market expansion. The creation of digital technology integration in healthcare, is expected to contribute towards the market growth during the period.
The North America region accounted for the largest share in the global genitourinary drugs market in 2022. The region is further projected to continue dominating in the market during the forecast period. This can be attributed to the emphasis on healthcare and growing geriatric population.
According to disease, urinary tract infections (UTIs) segment, the portable dialysis machines for home use segment accounted for the largest market share in the genitourinary drugs market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
The global genitourinary drugs market is segmented into disease, product, end-users and region. Based on disease, the market is bifurcated into urinary tract infections, urinary incontinence & overactive bladder, kidney/renal cancer, genitourinary cancer, bladder cancer, cervical cancer, sexually transmitted diseases, interstitial cystitis, hematuria, ovarian cancer, prostate cancer, others. Based on product, it is classified into urological, hormonal therapy, gynecological, anti-infectives, others. Based on end-users, it is classified into hospitals, clinics, super specialty centers, others
The global genitourinary drugs market is analyzed across North America (U.S. & Canada), Europe (Germany, United Kingdom, France, Italy, Spain, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Indonesia, Thailand, Australia, New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America) and Middle East & Africa (GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, and Rest of Middle East & Africa).
Key Insights of Genitourinary Drugs Market
- On the basis of disease, urinary tract infections (UTIs) segment accounted for the largest market share in the genitourinary drugs market in 2022 and is further expected to continue with the trend during the forecast period i.e., 2023 – 2032.
- On the basis of region, North America accounted for the largest share in the global genitourinary drugs market in 2022. The region is further projected to continue dominating in the market during the forecast period.
- On the basis of region, Europe is estimated to account for the second largest share in the market during the forecast period.
Some of the major genitourinary drugs companies profiled in the report include Allergan plc (AbbVie Inc.), Antares Pharma Inc., AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Genentech Inc. (Roche Holding AG), GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc. and Teva Pharmaceutical Industries Ltd.
Related Reports :-
https://www.kdmarketinsights.com/reports/pulmonary-embolism-treatment-market/7151
https://www.kdmarketinsights.com/reports/stomach-cancer-treatment-market/7148
https://www.kdmarketinsights.com/reports/systemic-mastocytosis-market/7147
